In this phase 1B study, avelumab (anti-PD-L1 antibody) used as a single-agent in 125 patients with previously relapsed platinum-resistant OC showed encouraging anti-tumor activity, with an objective response rate (ORR) of 9.6% and an acceptable toxicity profile. This evidence concerns the gene CD274 and neoplasm.